A Phase II Pilot Study of Dovitinib (TKI258) in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 14 May 2018
At a glance
- Drugs Dovitinib (Primary)
- Indications Adenoid-cystic-carcinoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 04 Apr 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 02 Jun 2015 Status changed from active, no longer recruiting to completed, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.